Drug intelligence / Profile preview

Shen Ling Gu Ben

Development stage: Preclinical
Lead developer: Jiangzhong Pharmaceutical
Administration: Oral

Overview

Shen Ling Gu Ben is a Traditional Chinese Medicine (TCM) formulation, often prepared as immune granules. It is currently under investigation for its potential to promote immune reconstruction in HIV/AIDS patients who exhibit inadequate responses to combined antiretroviral therapy. The drug aims to prevent aberrant immunological activation and address immune reconstitution deficiency, leveraging principles of traditional Chinese medicine.

Other names: Shen Ling Gu Ben immune granulesShenling Guben Granules

Beyond the preview

Go deeper on Shen Ling Gu Ben.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shen Ling Gu Ben.

Explore the full profile